Metagenomi Therapeutics, Inc. (MGX) SEC filings

MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30

$0.69−0.02 (-3.12%)

Close on Nov 13, 2026Market cap $26.13MP/E –Yield –

SEC filings

38 of Metagenomi Therapeutics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 10, 2026	SEC EDGAR
Current report	8-K	Nov 10, 2026	Nov 10, 2026	SEC EDGAR
Current report	8-K	Sep 21, 2026	Sep 22, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 10, 2026	SEC EDGAR
Current report	8-K	Aug 10, 2026	Aug 10, 2026	SEC EDGAR
Current report	8-K	Jun 9, 2026	Jun 10, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 11, 2026	SEC EDGAR
Current report	8-K	May 11, 2026	May 11, 2026	SEC EDGAR
Proxy statement	DEF 14A	Apr 21, 2026	Apr 27, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 5, 2026	SEC EDGAR
Current report	8-K	Mar 5, 2026	Mar 5, 2026	SEC EDGAR
Current report	8-K	Jan 12, 2026	Jan 12, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 12, 2025	SEC EDGAR
Current report	8-K	Nov 11, 2025	Nov 12, 2025	SEC EDGAR
Current report	8-K	Sep 29, 2025	Oct 1, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 12, 2025	SEC EDGAR
Current report	8-K	Aug 12, 2025	Aug 12, 2025	SEC EDGAR
Current report	8-K	Jun 10, 2025	Jun 11, 2025	SEC EDGAR
Current report	8-K	May 14, 2025	May 14, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 13, 2025	SEC EDGAR
Current report	8-K	May 13, 2025	May 13, 2025	SEC EDGAR
Proxy statement	DEF 14A	Apr 25, 2025	Apr 28, 2025	SEC EDGAR
Current report	8-K	Mar 17, 2025	Mar 17, 2025	SEC EDGAR
Current report	8-K	Mar 17, 2025	Mar 17, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 17, 2025	SEC EDGAR
Current report	8-K	Jan 13, 2025	Jan 16, 2025	SEC EDGAR
Current report	8-K	Dec 9, 2024	Dec 10, 2024	SEC EDGAR
Current report	8-K	Nov 13, 2024	Nov 13, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 13, 2024	SEC EDGAR
Current report	8-K	Sep 3, 2024	Sep 3, 2024	SEC EDGAR
Current report	8-K	Aug 14, 2024	Aug 14, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 14, 2024	SEC EDGAR
Current report	8-K	May 14, 2024	May 14, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	May 14, 2024	SEC EDGAR
Current report	8-K	Apr 26, 2024	May 1, 2024	SEC EDGAR
Current report	8-K	Mar 27, 2024	Mar 27, 2024	SEC EDGAR
Annual report	10-K	Dec 31, 2023	Mar 27, 2024	SEC EDGAR
Current report	8-K	Feb 13, 2024	Feb 13, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Metagenomi Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is MGX.

Compare: MGX vs SGMOQ · MGX vs EDIT · MGX vs CRSP · MGX vs RLAY · MGX vs DTIL

Revenue growth-51.8% · median 7.4%

Operating margin-396.5% · median -357.5%

Net margin-373.6% · median -356.9%

Company	Revenue	Growth
EDIT	$49.83M	+7.4%
DTIL	$45.04M	+6353.0%
SGMOQ	$34.56M	-45.8%
MGX	$25.21M	-51.8%
CRSP	$25.17M	-34.3%
RLAY	$10.35M	+23.9%

Company

Next earnings (est.): Mar 4, 2027, during market hours
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 119
Held by institutions: 16.6%
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 1785279

Advertisement
300 × 250

See a number that looks wrong?